Aescap-backed Biocartis acquires Philips Technology Platform
Aescap-backed molecular diagnostics company Biocartis has acquired Philips’ technology platform for rapid fully-automated DNA/RNA molecular diagnostic testing.
The platform has been designed for applications in a wide range of patient sample testing, including oncology and infectious diseases.
Biocartis will develop and commercialise the platform, together with a menu of tests, through strategic partnerships and will finalize validation of the platform at its newly established and wholly-owned Dutch subsidiary Biocartis BV.
More on Portfolio management
NorthEdge sells Belfield Group's Usleep
Mattress producer is to be acquired by Vita Group, a portfolio company of Strategic Value Partners
Clessidra's Botter bolts on Mondodelvino
Combined group expects to reach revenues of €350m in 2020 and further expand its market share
Bid Equity's Myneva bolts on Patronis, TTS
Social care and healthcare software platform is following a buy-and-build strategy
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Czech Republic-headquartered family office is targeting DACH and CEE region deals
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds